The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification

European Journal of Haematology
Vibor MilunovićSlobodanka Kolonić Ostojić

Abstract

Myelodysplastic syndromes (MDS) are heterogeneous group of hematologic disorders of mostly elderly and based on distinct clinical phenotypes. Current paradigm of their pathogenesis relies on somatic gene mutations combined with the predisposing defective osteohematopoietic niche, but due to the breakout in epigenetic research scientific focus has steered toward two most common epigenetic modifications: methylation mechanisms and histone modification. At the same time, relatively few studies have been undertaken regarding the third epigenetic pathway - microRNAs - in MDS. The main aim of this review is to provide the basics of microRNA biology and function in oncogenesis, showing the complexity of mechanisms behind this single-stranded 22 nucleotides long RNA molecule, with further focus on its implication in MDS pathology and clinical context. By extensive literature search, we have shown enough evidence for their deregulation in MDS. However, few studies have addressed the issue on pathogenic events in MDS and its association with specific microRNAs. Preliminary research in clinical setting has shown the possible utility of microRNAs in terms of prognosis and therapy, although we are only beginning to understand various implic...Continue Reading

References

Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Oct 4, 2008·Blood·Ying JiangJaroslaw P Maciejewski
Oct 17, 2008·PloS One·Ming LuQinghua Cui
Sep 17, 2009·Journal of the National Cancer Institute·Rabiya S Tuma
Nov 4, 2009·Leukemia & Lymphoma·Aina PonsMariano Monzo
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Torsten HaferlachRobin Foà
Jun 29, 2010·Cell Cycle·Stephan Emmrich, Brigitte M Pützer
Jul 16, 2010·Leukemia Research·Kais HusseinOliver Bock
Dec 15, 2010·European Journal of Human Genetics : EJHG·Michaela Dostalova MerkerovaJaroslav Cermak
Feb 22, 2011·British Journal of Haematology·Lubomir SokolAlan F List
Jun 28, 2011·Experimental Hematology·Begum ErdoganAnnette S Kim
Aug 20, 2011·Leukemia·G W Rhyasen, D T Starczynowski
May 11, 2012·Current Pharmaceutical Design·Jacqueline BoultwoodJames S Wainscoat
Jun 6, 2012·Nature Structural & Molecular Biology·Marc R Fabian, Nahum Sonenberg
Oct 11, 2012·International Journal of Cancer. Journal International Du Cancer·June Li
Jun 14, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Diamantina VasilatouVasiliki Pappa
Sep 14, 2013·Blood·Elli PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Sep 28, 2013·Cancer Discovery·Florian A Karreth, Pier Paolo Pandolfi
Oct 2, 2013·Annual Review of Pathology·Gianpiero Di LevaCarlo M Croce
Oct 19, 2013·Blood·Mario CazzolaLuca Malcovati
Jan 29, 2014·Cellular and Molecular Life Sciences : CMLS·Anna Stroynowska-CzerwinskaWlodzimierz J Krzyzosiak
May 17, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·John R ChevilletKai Wang
Jul 17, 2014·Nature Reviews. Molecular Cell Biology·Minju Ha, V Narry Kim
Aug 12, 2014·CA: a Cancer Journal for Clinicians·Ioana Berindan-NeagoeGeorge A Calin
Sep 23, 2014·Blood·Rafael Bejar, David P Steensma
Nov 11, 2014·International Journal of Molecular Sciences·Michael KarbienerMarcel Scheideler

❮ Previous
Next ❯

Citations

Apr 10, 2018·Cancer Biomarkers : Section a of Disease Markers·Zdenek KrejcikMichaela Dostalova Merkerova
Aug 9, 2021·The American Journal of Pathology·Dahai WangAnnette S Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.